Cholesterol synthesis inhibitors in cholesterol gallstone disease

Scandinavian Journal of Gastroenterology, Supplement

Volumn 31, Issue 218, 1996, Pages 56-60

  Smit, J W A ^a,b   Vanerpecum, K J ^a   Vanberge Henegouwen, G P ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bile; Cholesterol; Gallbladder; Gallstones; HMG CoA redutase inhibitors; Motility

Indexed keywords

BILE SALT; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHOLIPID; HYDROLYASE; METHYLGLUTACONYL COA HYDRATASE; METHYLGLUTACONYL-COA HYDRATASE;

BILE; BILE SECRETION; CHOLELITHIASIS; CHOLESTEROL STONE; CHOLESTEROL SYNTHESIS; CONFERENCE PAPER; GALLBLADDER MOTILITY; GALLSTONE DISSOLUTION; GALLSTONE FORMATION; HYPERCHOLESTEROLEMIA; PRIORITY JOURNAL; ANIMAL; BIOSYNTHESIS; CHEMISTRY; CLINICAL TRIAL; HUMAN; PROGNOSIS; REVIEW;

ANIMALS; CHOLELITHIASIS; CHOLESTEROL; CLINICAL TRIALS; HUMANS; HYDRO-LYASES; PROGNOSIS;

EID: 0029779373     PISSN: 00855928     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365529609094732     Document Type: Conference Paper

References (3)

1. Angelin B. Regulation of hepatic cholesterol metabolism in man. Ann Med 1991;23:177-80.
2. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolaemia. N Engl J Med 1988;319:24-33.
3. Maher VM, Thompson GR. HMG-CoA reductase inhibitors as lipid lowering agents: five years' experience with lovastatin and appraisal of simvastatin and pravastatin. Q J Med 1990:74:165-75.